MERTK and melanoma: Our data identify MerTK as a novel mediator of cancer cell survival driven by mTORC1/autophagy signaling, and suggest that combinatorial inhibition of BRAFV600E and the autophagy/MerTK axis provides a novel therapeutic strategy to overcome acquired resistance to BRAFi or BRAFi/MEKi in melanoma patients.